<DOC>
	<DOCNO>NCT00164060</DOCNO>
	<brief_summary>The purpose study examine effect GB virus C ( GBV-C ) natural history chronic hepatitis C virus ( HCV ) infection subject co-infected HIV HCV . The aspect study assess effect GBV-C severity liver disease due chronic hepatitis C subject co-infected HIV HCV . This do determine point prevalence co-infection retrospectively follow cohort prospectively . In addition , individual recruit prospective manner .</brief_summary>
	<brief_title>Associations , Outcomes Genomics GB Virus C , Hepatitis C Virus Human Immunodeficiency Virus Infection</brief_title>
	<detailed_description>Background Research Plan : GBV-C hepatitis G virus ( HGV ) RNA viruses Flaviviridae family . Molecular characterization virus show virtually identical ( 1,2 ) . GBV-C first isolate 1995 archival blood sample obtain 1960s surgeon acute non A-E hepatitis ( 3 ) . GBV-C 29 % amino acid sequence homology Hepatitis C Virus ( HCV ) , another flavivirus ( 4 ) . However , GBV-C contrast HCV , hepatotropic virus neither replicates primarily hepatocytes cause acute chronic hepatitis . Indeed , GBV-C cause specific disease represent substantial health risk human . Nevertheless , GBV-C infection relatively common 2 % prevalence rate healthy blood donor , majority clear virus develop antibody envelope glycoprotein E2 . HIV infection particularly high rate co-infection GBV-C. Studies suggest co-infection lead beneficial effect course HIV ( 5,6,7 ) co-infection associate significantly low mortality rate among HIV-infected subject compare infected GBV-C . The mechanism beneficial effect GBV-C course HIV infection obscure . Among new case non-A , non-B hepatitis United States , 18 percent positive GBV-C , 80 % patient also infect HCV . Amongst patient HCV , 10-20 % GBV-C RNA serum ( 4 ) . In another report 189 patient chronic HCV infection evaluate ; 21 ( 11 % ) positive GBV-C RNA ( 8 ) . The course HCV infection response interferon-alfa affected co-infection GBV-C. Interferon-alfa lead decrease GBV-C RNA titer sustain cessation therapy . Similar finding note another study liver biopsy perform ( 9 ) . Detailed histopathologic examination reveal difference patient infected HCV alone 15 percent co-infected GBV-C . There study date look effect GBV-C , HCV HIV . Our previous study HIV GBV-C suggest co-infection common . Active GBV-C infection frequently observe person involve high-risk sexual activity HIV infection . Homosexual intercourse appear effective mean transmission GBV-C. GBV-C epidemiology transmission HIV underline intimate association GBV-C HIV ( 10 ) . Methods/Experimental Design : Stored serum available people attend Hepatitis HIV clinic Alfred Hospital . Sera available back approximately 1990 store minus 20ÂºC suitable GBV-C detection particularly RNA PCR . Of serum store HIV clinic 203 patient know co-infected HCV currently still alive . Once ethics committee approval obtain propose contact group people see would participate study . Once consent obtain plan perform follow . A . Stored serum retrospectively examine point prevalence infection HCV , GBV-C HIV . These individual follow prospective manner assess progression liver disease factor outline Tables 1 4 . B . New subject attend Alfred Hospital Hepatitis HIV clinic recruit followed prospectively also outline Tables 1 4 . C. An age sex match control group infect HCV alone identify via Alfred Hospital Hepatitis clinic . This clinic large cohort well-characterized HCV infect subject extend back 1989 . The inclusion exclusion criterion study follow : Inclusion criterion 1 . Sera available appropriate testing . Including serial serum period time . ( retrospective analysis ) 2 . HIV serology positive . 3 . Unequivocal HCV antibody positive HCV RNA positive . Exclusion criteria 1 . Those without serum available . 2 . Those unwilling give inform consent . 3 . Persons Hepatitis B Virus infection , define presence Hepatitis B surface antigen and/or Hepatitis B Virus DNA positive . Where possible information also obtain people interview , examine medical record discussion General Practitioners . Subjects also encourage attend hospital person clinical exam perform . If insufficient serum store blood drawn time examine HCV , HIV GBV-C related parameter outline table . A study specific questionnaire generate subject ask complete confidential questionnaire contains information relate demographic behavioral factor may contribute acquisition GBV-C , HCV HIV infection various combination . Demographic variable include age , sex , country birth , occupation . Information relevant HIV infection include use HAART presence absence AIDS defining syndrome obtain . The questionnaire attempt identify approximate time acquisition HCV HIV . In addition , extent liver disease assess , alcohol consumption quantify information gather previous treatment Interferon Ribavirin . The main outcome study liver relate morbidity , chronic hepatitis , cirrhosis hepatocellular cancer overall patient survival . The detailed information contain follow table obtain interview , medical record clinical examination : Table 1 : GBV-C 1 . Testing sera GBV-C RNA E2 antibodies GBV-C. 2 . Performing test one-year interval serum available . Table 2 : HIV 1 . CD4 count ( buffy coat ) HIV positive . 2 . HIV viral load . 3 . Use highly active antiretroviral therapy ( HAART ) retroviral treatment and/or change treatment . 4 . Complications HIV/AIDS AIDS defining illness . Table 3 : Liver disease ( HCV ) 1 . HCV viral load genotype . 2 . Child-Pugh classification base level bilirubin , albumin clot profile , presence ascites encephalopathy . 3 . Complications liver disease : ascites , encephalopathy , variceal bleed hepatocellular carcinoma . 4 . ALT AST level well AST/ALT ratio . 5 . Alpha Feto Protein ( AFP ) level . 6 . Liver histology biopsy assessment inflammation grade , stage fibrosis severity hepatic steatosis . 7 . Liver ultrasound result . 8 . Results endoscopy , i.e . feature portal hypertension Table 4 : Survival Data 1 . Has patient die ? 2 . Date death . 3 . Cause death . Results statistically examine univariate multivariate analysis term clinical outcome respect chronic hepatitis C liver disease GBV-C positive negative group HIV co-infected cohort compare HCV infected cohort alone . See follow Table 5 . Table 5 : Study Design Study Group No.1 HCV +ve , HIV +ve , GBV-C RNA+ve . Study Group No.2 HCV +ve , HIV +ve , GBV-C RNA-ve . Control Group HCV +ve alone . References relevant project ( literature search ) 1 . Linnen J , Wages J , Zhang-Keck Z , et al . Molecular clone disease association hepatitis G virus : A new transfusion transmissible agent . Science 1996 ; 271:505-8 . 2 . Alter HJ . The clone clinical implication HGV HGBV-C. N Engl J Med 1996 ; 334:1536-7 . 3 . Simons JN , Leary TP , Dawson GJ , et al . Isolation novel virus-like sequence associate Human hepatitis . Nat Med 1995 ; 1:564-9 . 4 . Di Bisceglie AM . Hepatitis G virus infection : A work progress . Ann Intern Med 1996 ; 125:772 . 5 . Tillman HL , Heiken H , Knapik-Botor A , et al . Infection GB virus C reduce mortality among HIV-infected patient . N Engl J Med 2001 ; 345:715-24 . 6 . Xiang J , Wunschmann S , Diekema DJ , et al . Effect coinfection GB virus C survival among patient HIV infection . N Engl J Med 2001 ; 345:707-14 . 7 . Lefrere JJ , Roudot-Thoraval F , Morand-Joubert L , et al . Carriage GB virus C/hepatitis G virus RNA associate slow immunologic , virologic clinical progression human Immunodeficiency virus disease coinfected person . J Infect Dis 1999 ; 179:783-9 . 8 . Tanaka E , Alter HJ , Nakatsuji Y , et al . Effect hepatitis G virus infection chronic hepatitis C. Ann Intern Med 1996 ; 125:740-3 . 9 . Bralet MP , Roudot-Thoraval F , Pawlotsky JM , et al . Histopathologic impact GB virus C infection chronic hepatitis C. Gastroenterology 1997 ; 112:188-92 . 10 . Berzsenyi MD , Bowden SD , Bailey MJ , et al . Sexual blood-borne transmission GB virus C association Human Immunodeficiency Virus . In press .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>1 . Sera available appropriate testing , include serial serum period time ( retrospective analysis ) 2 . HIV serology positive . 3 . Unequivocal HCV antibody positive HCV RNA positive . 1 . Those without serum available . 2 . Those unwilling give inform consent . 3 . Persons hepatitis B virus infection , define presence hepatitis B surface antigen and/or hepatitis B virus DNA positive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>HCV</keyword>
	<keyword>HIV co-infection</keyword>
</DOC>